secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274596
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports positive lonvo-z HAE data: 97% attack-free; nex-z shows 87% TTR reduction at 36 months
--------------------------------------------------------------------------------

- Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).
- Mean kallikrein reduction 89% at month 24; well-tolerated safety up to 3 years with no long-term risks.
- Nex-z Phase 1: 87% mean serum TTR reduction at 36 months (n=9); all-cause mortality rate 3.9 vs 12.7 per 100 patient-years (HR 0.27, p=0.009) vs matched cohort.
- Nex-z showed disease stability or improvement on multiple cardiomyopathy markers at 24 months; 81% stable/improved NYHA class.
- FDA clinical hold on nex-z Phase 3 MAGNITUDE/MAGNITUDE-2 trials; company working to address.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/0001193125-25-274596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/d12611d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer